Answers are grounded in this paper and cite their sources.
OverviewAdverse events (AEs) related to the use of immune checkpoint inhibitor (ICI) therapy are defined as immune-related (IR) AEs (irAEs).irAEs are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (Supplementary Table S1, available at https://doi.org/10. 1016/j.annonc.2022.10.001). 1 The aim of this European Society for Medical Oncology (ESMO) Clinical Practice Guideline (CPG) is to provide specific guidance on irAE management.Recommendations provided are based on evidence from the scientific literature, clinical experience and analogy to the treatment of autoimmune diseases (ADs), where appropriate.Consensus for the recommendations was obtained by direct communication, scientific debate and agreement.Further information regarding the provision of patient information, routine baseline screening before ICI initiation, monitoring during ICI therapy, management of outpatients versus inpatients and that of corticosteroid (CS)-refractory patients and patients with specific conditions can be found in Section 1 of the Supplementary Material, available at https://doi.org/10.1016/j.annonc.2022.10.001. General guidance for immunosuppressionirAE management generally consists of four sequential steps: (i) diagnosis and grading of irAEs, (ii) ruling out differential diagnoses and pre-immunosuppression work-up, (iii) selecting the appropriate immunosuppression strategy for grade !2 events and (iv) active evaluation at 72 h to adapt treatment.See Supplementary Table S2 and Section 1 of the Supplementary Material, available at https://doi.org/ 10.1016/j.annonc.2022.10.001.To minimise the occurrence of CS-induced AEs, the following general guidance is proposed 2 :The lowest effective CS dose should be prescribed for the shortest possible duration, which, in general will be several weeks for grade !3 irAEs, including tapering CS therapy tapering or discontinuation only on medical advice Lifestyle adaptations to minimise the risk of CS-induced AEs Immunosuppressive drugsOptimising the choice of immunosuppressive agents.Prospective studies evaluating the safety and efficacy of immunosuppressant agents in irAE management are
No takes yet. Share an insight, caveat, or question.
Haanen et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: